0336 GMT - ResMed's expanded U.S. manufacturing footprint is seen by Goldman Sachs analysts as likely to further assist strong gross margin accretion at the breath-tech manufacturer. A 70bp expansion in 3Q gross margin was key to ResMed's stronger-than-expected profit for the period, they say. Keeping a buy rating on the stock, the analysts tell clients in a note that margin accretion to date reflects operating leverage from manufacturing capacity expansion, discipline on labor costs, and the optimization of raw materials. GS lifts its target price by 5.1% to A$49.30. Shares are down 0.7% at A$36.68. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 28, 2025 23:36 ET (03:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。